After treating IPF lung fibroblasts with Lapatinib, decreased p-HER2 levels were observed in a dose-dependent manner (Fig. 7 G), suggesting that Lapatinib was effective in blocking HER2 signaling in IPF lung fibroblasts. The gene discussed is ERBB2; the disease is idiopathic interstitial pneumonia.